Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
United States95 participantsStarted 2022-04-12
Plain-language summary
Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Age ≥50 years.
* Non-exudative age-related macular degeneration defined as AREDS category 3 Intermediate AMD and/or geographic atrophy
* Best-corrected distance visual acuity 20/40 to 20/200 (inclusive) in the study eye, and BCVA 20/100 or better in the fellow eye
Key Exclusion Criteria:
* History and/or evidence of exudative age-related macular degeneration in either eye
* History and/or evidence of diabetic retinopathy in either eye
* Current tobacco or tobacco-related product use or history within the past 10 years of heavy smoking (on average, more than half a pack of cigarettes per day)
* Central chorioretinal atrophy in the study eye
* Glaucoma in the study eye
What they're measuring
1
Adverse Device Effects
Timeframe: Through study completion, Month 12 timepoint